Dr. Bordignon, MolMed’s Founder, has an established international reputation as a pioneer in gene and cell therapy and is widely known for the clinical validation of several successful gene therapy protocols for both genetic and acquired disorders, including leukemias and other malignancies. He is the author of more than 150 publications and inventor of several patents, that represent crucial components of the company’s core technologies. He is professor of hematology at the University Vita-Salute San Raffaele Medical School and Director of the Clinical Training Program in hematology. In 2005, he was appointed by the EU Commission as one of the 22 eminent members of the Scientific Council of the European Research Council.
He served as scientific director of the San Raffaele Scientific Institute (1998 to 2006) and held positions as director of Hematology, head of the Gene Therapy and Bone Marrow Transplantation Program. Dr. Bordignon received his M.D. degree from the School of Medicine of the University of Milan and completed his medical and science training during eight years spent in several of the most prestigious U.S. institutions, including four years at Memorial Sloan Kettering Cancer Center (New York).